Skip to content

Study · Randomized controlled trial · 2023

4 results

Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.

McGowan BM, Houshmand-Oeregaard A, Laursen PN, Zeuthen N, Baker-Knight J

Obesity (Silver Spring, Md.)6 Mar 2023Cited by 13 (Europe PMC)

PMID36876594 (opens in a new tab)DOI10.1002/oby.23732 (opens in a new tab)PepBankPUB-36876594
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and baseline BMI below 35, semaglutide 2.4 mg reduced mean body weight by 16.2% from baseline to week 68 (p < 0.0001 versus placebo).

    In plain wordsIn adults with overweight or obesity and a BMI below 35, weekly semaglutide cut body weight by 16.2% over 68 weeks, significantly more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change to week 68, baseline BMI <35
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Body weight change
    −16.2%
    BMI <35, week 68

    Source sentences

    Summary
    Mean changes in body weight from baseline to week 68 with semaglutide were -16.2% and -14.0% in the subgroups with baseline BMI 2 , respectively (both p < 0.0001 vs. placebo).
    1 context sentence
    Summary · context
    This was a post hoc exploratory subgroup analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (NCT03548935), in which participants without diabetes and BMI ≥30 kg/m2 , or BMI ≥27 kg/m2 with ≥1 weight-related comorbidity, were randomized to once-wee…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity and baseline BMI of 35 or more, semaglutide 2.4 mg reduced mean body weight by 14.0% from baseline to week 68 (p < 0.0001 versus placebo).

    In plain wordsIn adults with overweight or obesity and BMI of 35 or more, weekly semaglutide cut weight by 14.0% over 68 weeks, significantly more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change to week 68, baseline BMI 35 or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Body weight change
    −14%
    BMI >=35, week 68

    Source sentences

    Summary
    Mean changes in body weight from baseline to week 68 with semaglutide were -16.2% and -14.0% in the subgroups with baseline BMI 2 , respectively (both p < 0.0001 vs. placebo).
    1 context sentence
    Summary · context
    This was a post hoc exploratory subgroup analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (NCT03548935), in which participants without diabetes and BMI ≥30 kg/m2 , or BMI ≥27 kg/m2 with ≥1 weight-related comorbidity, were randomized to once-wee…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity and comorbidities, prediabetes, or both prediabetes and high cardiovascular risk, semaglutide 2.4 mg produced body weight changes similar to the BMI subgroups.

    In plain wordsIn adults with obesity and added health conditions, weekly semaglutide cut body weight by similar amounts as in the BMI subgroups.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change in subgroups with comorbidities, prediabetes, and prediabetes plus high CVD risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar changes were observed in individuals with comorbidities, with prediabetes, and with prediabetes plus high CVD risk.
    1 context sentence
    Summary · context
    This was a post hoc exploratory subgroup analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (NCT03548935), in which participants without diabetes and BMI ≥30 kg/m2 , or BMI ≥27 kg/m2 with ≥1 weight-related comorbidity, were randomized to once-wee…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, the beneficial effects of semaglutide 2.4 mg on cardiometabolic risk factors were consistent across all BMI and comorbidity subgroups.

    In plain wordsIn adults with obesity, weekly semaglutide had similar benefits on heart and metabolic risk factors in all subgroups.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedCardiometabolic risk factors across subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    The beneficial effects of semaglutide on cardiometabolic risk factors were consistent across all subgroups.
    1 context sentence
    Summary · context
    This was a post hoc exploratory subgroup analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (NCT03548935), in which participants without diabetes and BMI ≥30 kg/m2 , or BMI ≥27 kg/m2 with ≥1 weight-related comorbidity, were randomized to once-wee…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03548935

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 1,9614 Jun 2018 to 5 Mar 2021

Metabolism and Nutrition Disorder · Overweight or Obesity

Trial pageClinicalTrials.govUpdated 19 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.